Pixyl
Pixyl is a French AI medical-device company that provides FDA-cleared and CE-marked software for automated brain MRI analysis, focused on multiple sclerosis lesion detection, brain volumetry, and longitudinal monitoring for radiology and neurology departments.
- Company typePrivate
- Founded2015
- HeadquartersLa Tronche, France
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Pixyl does
Pixyl SAS is a France-based (La Tronche) medical imaging AI company that develops proprietary computer-vision algorithms for automated analysis of brain MRI scans, primarily targeting neuroinflammatory and neurodegenerative disorders. The company's flagship platform, Pixyl.Neuro, comprises specialized modules — Pixyl.Neuro.MS for multiple sclerosis lesion segmentation and quantification, and Pixyl.Neuro.BV for brain volumetry — and is delivered as a regulated medical device: FDA 510(k)-cleared (Class II) and CE-marked Class IIa under EU MDR. Reported clinical performance includes up to 28% enhanced T2-FLAIR lesion detection versus unaided reads and up to 65% reduction in reading time, with analysis completed in under five minutes on minimal MR protocols; validation is anchored in peer-reviewed publications in Journal of Neuroradiology and collaborations with academic consortia (PRIMUS, ANR-funded) and GE Healthcare (AI DReAM).
Pixyl monetizes through enterprise licensing of its regulated AI software to hospital radiology and neurology departments, integrating into existing PACS/radiology workflows via a subscription model with quote-based pricing typical of Class II medical device software. The company's GTM is anchored in scientific publication, academic collaboration, and clinical validation rather than broad-based marketing, and customer reach is concentrated in healthcare-provider segments (radiology departments, neurologists, MS specialists, academic research centers). In 2025 Pixyl was acquired by French AI radiology peer Gleamer as part of a consolidation strategy, and in March 2026 Gleamer (including Pixyl) was itself acquired by US imaging group RadNet for €230 million, positioning Pixyl as RadNet's European AI hub for neurological imaging within the DeepHealth unit.
At the time of the RadNet transaction, the parent Gleamer business reported approximately €30 million ARR across roughly 700 clients in 44 countries, but no Pixyl-specific revenue, headcount, or unit economics have been disclosed. Prior to the Gleamer acquisition, Pixyl had raised approximately $3.3 million in disclosed funding (notably a 2021 round with Bpifrance, Elaia, and Holnest) and operated with 11–50 employees, indicating a focused R&D and clinical-validation stage rather than a scaled commercial operation.
Pixyl firmographics
Firmographics- Name
- Pixyl
- Legal name
- Pixyl SAS
- Website
- https://pixyl.ai
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Pixyl is a French AI medical-device company that provides FDA-cleared and CE-marked software for automated brain MRI analysis, focused on multiple sclerosis lesion detection, brain volumetry, and longitudinal monitoring for radiology and neurology departments.
- Ownership category
- akta.pro rank
Pixyl industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Medical Laboratories (621511)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)
- akta.pro secondary industry
- Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies (HLAAANAJ)
Keywords
Where Pixyl is headquartered
LocationHeadquarters
- HQ city
- La Tronche
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Pixyl business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- AI Medical Imaging Software Licensing: Pixyl generates revenue through licensing its AI-powered MRI analysis software as a medical device. Given the regulatory clearances (FDA, CE-mark) and B2B nature, the model likely involves annual subscription contracts with healthcare institutions.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Pixyl product offering
Product offeringCore offering
Pixyl develops and sells Pixyl.Neuro, an FDA-cleared class II and CE-marked class IIa AI medical device that performs automated brain MRI analysis for neuroinflammatory and neurodegenerative disorders, with a focus on multiple sclerosis. The software detects lesions, quantifies brain volumes, and produces structured diagnostic reports in under five minutes, integrating into existing radiology workflows. Pixyl also develops the PRIMUS research platform, a precision-medicine project combining AI lesion segmentation with clinical decision support for MS treatment selection.
Product overview
Pixyl is an AI radiology company focused on augmented MRI analysis for improved patient care. Now a Gleamer company, Pixyl's portfolio centers on Pixyl.Neuro, a unified AI platform for brain MRI analysis comprising specialized modules: Pixyl.Neuro.MS for multiple sclerosis diagnosis and follow-up, and Pixyl.Neuro.BV for brain volumetry. Pixyl.Neuro is certified as an FDA-cleared class II and CE-marked class IIa medical device under EU MDR, leveraging proprietary AI algorithms to deliver clinically actionable brain MRI insights in under five minutes.
Differentiator
Problem solved
Functional benefit
Brands
- Pixyl.Neuro: AI-powered solution for brain MRI analysis detecting anomalies for neuroinflammatory and neurodegenerative disorders, with FDA clearance and CE-mark certification.
- Pixyl.Neuro.MS
- Pixyl.Neuro.BV
Products and services
- Pixyl.Neuro AI-powered brain MRI analysis platform that detects anomalies and quantifies brain structures for neuroinflammatory and neurodegenerative disorders, providing automated lesion segmentation, brain volumetry, and structured diagnostic reports in under five minutes. FDA-cleared class II and CE-marked class IIa medical device under EU MDR, sold to radiology and neurology departments via enterprise licensing.
- PRIMUS (PRojections In MUltiple Sclerosis) Precision-medicine research platform for multiple sclerosis combining a brain MRI viewer with AI-powered lesion segmentation and a clinical decision support system for treatment selection based on similar-patient data. Led by an academic-IT-pharmaceutical consortium and supported by the French National Research Agency under reference ANR-21-RHUS-0014 as part of the France 2030 plan, targeting academic medical centers and research institutions.
Quantifiable outcome
- Up to 28% Enhanced Detection Rate for T2-FLAIR lesion detection and evolution
- +2 more outcomes
Companies that use Pixyl
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Pixyl technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
Pixyl partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- GleamercoreGleamer acquired Pixyl in 2025 as part of its consolidation strategy to expand into brain MRI analysis. Pixyl operates as Gleamer's European AI hub for neurological imaging solutions, with solutions including Pixyl.Neuro and Gleamer Copilot integrated into the portfolio.
- French National Research Agency (ANR)coreANR supports the PRIMUS (PRojections In MUltiple Sclerosis) precision medicine platform project as part of France 2030 plan under reference ANR-21-RHUS-0014. PRIMUS aims to provide neurologists and neuroradiologists with AI-powered tools for MS care pathway support, including brain MRI lesion segmentation and clinical decision support.
- GE HealthcarecoreCollaboration on AI DReAM (AI Diagnostic Research for Accelerated Medicine) initiative, a research project combining Pixyl's brain MRI AI expertise with GE Healthcare's imaging technology platform for advancing diagnostic capabilities.
- Rennes University HospitalcoreLead clinical partner for PRIMUS platform development. Rennes University Hospital provides official project description and serves as the primary clinical research site for validating MS precision medicine tools.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
Pixyl competitors and assessment
Company assessmentDirect peers
- icometrix: Belgium-based AI company with FDA-cleared icobrain platform for brain MRI quantification in MS, dementia, and traumatic brain injury. Most direct head-to-head competitor to Pixyl.Neuro.MS in the MS and brain volumetry space.
- Cortechs.ai: Developer of NeuroQuant, a long-established FDA-cleared brain MRI volumetric analysis tool widely used in clinical and research settings. Directly comparable to Pixyl.Neuro.BV for hippocampus, amygdala, and subcortical volumetry.
- Quibim: Spain-based AI radiology company with a strong neuroimaging and whole-body imaging focus, including quantitative MRI biomarkers. Directly comparable to Pixyl in applying AI to brain MRI analysis for clinical and research use.
- Imbio: AI imaging analysis company with FDA-cleared lung and chest CT analysis tools expanding into broader radiology AI workflows. Comparable as a similarly sized medical imaging AI specialist with regulatory clearances and enterprise sales motion.
Broad incumbents
- Aidoc: One of the largest AI radiology platforms covering CT and MRI across multiple anatomies and pathologies including neuro. Competes with Pixyl for hospital-wide radiology AI budgets, though Aidoc is broader and less specialized in MS/brain volumetry.
- Viz.ai: Enterprise radiology AI platform with strong neurology focus (stroke detection, care coordination). Larger and broader than Pixyl but overlaps in the neuroimaging category and competes for the same hospital procurement budgets.
- Qure.ai: India-based radiology AI company with FDA-cleared products across chest, head CT, and musculoskeletal imaging. Competes with Pixyl in enterprise sales to multi-site hospital networks seeking consolidated AI platforms.
- RapidAI: Medical imaging AI platform primarily focused on neurovascular and stroke imaging with enterprise hospital deployments. Competes for the same neurology imaging budgets as Pixyl and represents a broader-platform alternative.
- Arterys: Cloud-native radiology AI platform with FDA-cleared products across cardiac and oncologic imaging. Operates in adjacent enterprise radiology AI category and competes for the same hospital imaging IT consolidation budgets.
Others
- Gleamer: Former competitor in AI radiology now Pixyl's parent company (since 2025) and central distribution platform. Included as a peer because it absorbed Pixyl's offering into its portfolio and jointly addresses the radiology AI market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Pixyl social profiles
Digital presencePixyl compliance and trust
Trust signalCompliance2 records
Pixyl financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pixyl leadership team
Management profileNumber of profiles
Profiles3 records
Pixyl funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pixyl M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pixyl
What does Pixyl do?
Pixyl develops and sells Pixyl.Neuro, an FDA-cleared class II and CE-marked class IIa AI medical device that performs automated brain MRI analysis for neuroinflammatory and neurodegenerative disorders, with a focus on multiple sclerosis. The software detects lesions, quantifies brain volumes, and produces structured diagnostic reports in under five minutes, integrating into existing radiology workflows. Pixyl also develops the PRIMUS research platform, a precision-medicine project combining AI lesion segmentation with clinical decision support for MS treatment selection.
Is Pixyl a public or private company?
Pixyl is a private company. It is classified as corporate owned and is currently operating.
When was Pixyl founded?
Pixyl was founded in 2015. It employs 1 to 10 people.
Where is Pixyl based?
Pixyl is headquartered in La Tronche, France, in the Europe region.
How does Pixyl make money?
One revenue line is on record: AI Medical Imaging Software Licensing.
Who are Pixyl's main competitors?
Direct peers on record are icometrix, Cortechs.ai, Quibim and Imbio. Broad incumbents are Aidoc, Viz.ai, Qure.ai, RapidAI and Arterys. Gleamer is listed as an others.
Does Pixyl have an API?
No public API is recorded for Pixyl.
What industry is Pixyl in?
Pixyl's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms, with a secondary code of HLAAANAJ, Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies. Its NAICS code is 621511 and its SIC code is 3845.